Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary

• Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors.
• Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst.
• The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.
• Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors.
• CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches.

Morsa Images

Cardiff Oncology Overview

Cardiff Oncology, Inc. (CRDF) is a clinical stage biotech that leverages Polo-like Kinase 1 (“PLK1”) inhibition as it attempts to develop novel therapies across a range of cancers. Its lead drug candidate is Onvansertib, a drug

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRDF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.